The ALLG clinical trial program addresses the broad range of issues that a patient experiences during their cancer journey. ALLG trials focus not only on evaluating the effectiveness of new treatments, but also patients’ quality of life and the cost-effectiveness of therapies.


All ALLG research is conducted at the highest ethical and regulatory standards. Most ALLG trials are randomised phase II or III controlled trials, which are the most definitive method to determine the effectiveness or ineffectiveness of a cancer treatment.

Many ALLG trials are multidisciplinary and involve collaborations with other Australasian and international collaborative cancer trial groups and researchers.

Integral to blood cancer research in Australia and New Zealand is the Australasian Leukaemia & Lymphoma Biobank. Patients who participate in ALLG clinical trials have an opportunity to donate blood, tumour or other tissue to the Biobank for further research. This research is necessary to better predict how well treatments will work and to develop better ways to detect and treat blood cancer.

By effectively bridging the gap between clinical trials and core biomedical research, the ALLG Biobank is pivotal to accelerating blood cancer research in Australia and New Zealand.

Since inception in 1973, the ALLG and its predecessors have activated more than 160 clinical trials in Australia and New Zealand. This ground-breaking research continues to influence the way doctors treat blood cancer patients globally.